Flow cytometry features of SMZL and other leukemic B-cell lymphoproliferative disorders
| . | SMZL . | CLL . | MCL . | HCL . | HCL-v . |
|---|---|---|---|---|---|
| sIg | Strong | Weak | Strong | Strong | Strong |
| CD5 | + | +++ | +++ | − | − |
| CD23 | + | +++ | − | − | − |
| FMC7 | +++ | + | +++ | +++ | +++ |
| CD11c | ++ | − | − | +++ | +++ |
| CD103 | − | − | − | +++ | ++ |
| CD123 | − | − | − | +++ | − |
| CD25 | + | − | − | +++ | − |
| CD27 | ++ | +++ | +++ | − | ++ |
| CD200 | − | +++ | − | +++ | − |
| . | SMZL . | CLL . | MCL . | HCL . | HCL-v . |
|---|---|---|---|---|---|
| sIg | Strong | Weak | Strong | Strong | Strong |
| CD5 | + | +++ | +++ | − | − |
| CD23 | + | +++ | − | − | − |
| FMC7 | +++ | + | +++ | +++ | +++ |
| CD11c | ++ | − | − | +++ | +++ |
| CD103 | − | − | − | +++ | ++ |
| CD123 | − | − | − | +++ | − |
| CD25 | + | − | − | +++ | − |
| CD27 | ++ | +++ | +++ | − | ++ |
| CD200 | − | +++ | − | +++ | − |
−, <10% of cases positive; +, 11%-35% positive cases; ++, 36%-75% positive cases; +++, >75% positive cases.
CLL, chronic lymphocytic leukemia; MCL, mantle cell lymphoma; sIg, superficial immunoglobulin expression.